Trial Profile
Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC): An Adaptive Design Dose Escalation Trial With Addition of Standard Doxorubicin Treatment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs BCT 100 (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Pharmacokinetics; Therapeutic Use
- 13 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2009 New trial record